The combination of ruxolitinib and MK2206 inhibits cell growth via activating P53 and PTEN expression and decreasing PI3K expression in triple negative breast cancer cell line
European Human Genetics Virtual Conference 2021, 28 August 2021, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Bilecik Şeyh Edebali University Affiliated: Yes